AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01490593 — intervention group
Intervention type: BEHAVIORAL
Intervention: Public Health strategies
Description: It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
Study NCT03638492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2-cm margin
Description: Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
Study NCT03638492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4-cm margin
Description: Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
Study NCT00486902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
Study NCT00486902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
Study NCT03396289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy including balance exercises
Description: Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
Study NCT03396289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy including balance exercises
Description: Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
Study NCT02478567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Training
Description: four specific band-resisted strength training exercises for scapula
Study NCT02478567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Training
Description: four specific band-resisted strength training exercises for rotator cuff
Study NCT01869309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
Study NCT03396289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
Study NCT03378570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
Study NCT00704470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical simulator training
Description: Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
Study NCT00704470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator based crew resource management course
Description: Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
Study NCT02123914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with Vit. C
Description: walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
Study NCT04406571 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: Data record
Study NCT02363829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Study NCT02363829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02314806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation with gentamicin solution
Description: The surgical bed is irrigated with a gentamicin solution
Study NCT02314806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation with Clindamycin solution
Description: The surgical bed is irrigated with a clindamycin solution
Study NCT02314806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irrigation with Normal saline
Description: The surgical bed is irrigated with normal saline
Study NCT03735485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program.
Study NCT02123914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise with Vit. C
Description: walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
Study NCT02123914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
Study NCT02123914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment.
Study NCT04503733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (300 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Study NCT02154594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acacia catechu
Study NCT02154594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acacia catechu
Study NCT04503733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (600 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Study NCT04503733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (1000 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Study NCT04503733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q4W GMA301 IV injections (1800 mg)
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Study NCT02154594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acacia catechu
Study NCT04503733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q4W placebo IV injections
Description: Placebo is indistinguishable from GMA301.
Study NCT02154594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study NCT01837576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus BDP gel in different doses
Description: Topical , Once daily, 3 weeks
Study NCT00709579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RV3391A
Description: A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
Study NCT00709579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02154594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Study NCT02154594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine gluconate
Study NCT02154594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distilled water
Study NCT01869309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
Study NCT02197156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg HC-ER
Description: Single dose
Study NCT02154594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distilled water
Study NCT02154594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Study NCT00687453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine at bedtime instead of NPH
Description: Insulin glargine at bedtime substituting for NPH insulin at bedtime
Study NCT00687453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH twice-daily
Description: Addition of morning NPH to bedtime NPH
Study NCT01596179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive navigational support
Description: Interactive navigational support is provided by a nurse and social worker navigators
Study NCT02051075 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PXN sperm treatment
Description: immotile sperm activation with PXN
Study NCT02051075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sperm activation with PXN and oocyte activation
Study NCT01920646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALV
Description: Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
Study NCT01311869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EGCG ( Green Tea extract)
Description: A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
Study NCT01311869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EGCG ( Green Tea extract)
Description: A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
Study NCT01311869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Brown rice pills
Description: 40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
Study NCT01311869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brown rice pills
Description: 40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
Study NCT03735485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Mobilization
Description: In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
Study NCT03735485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist.
Study NCT03301948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeed
Description: Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
Study NCT01596179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet access
Description: a netbook computer with internet access is provided to participants on the control arm.
Study NCT01249235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patch or bandage contact lens
Description: Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
Study NCT01249235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patch or bandage contact lens
Description: Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
Study NCT00864760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg tablets, single dose (1 tablet)
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT00864760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Study NCT01451593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
Study NCT01451593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo identical in appearance to active IMP (phenytoin)
Study NCT01996787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Study NCT01996787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti with Handling Tint
Description: Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Study NCT03051633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Under Your Own Influence
Description: School based anti-drug use communications campaign
Study NCT01146470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC
Description: dosage of Red Grape Cells once a day, during 3 months
Study NCT01146470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage of Placebo once a day, during 3 months
Study NCT02145962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm tissue exposure with ELF-MF
Description: The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
Study NCT02145962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thorax tissue exposure with ELF-MF
Description: The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
Study NCT01035190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation, 200 µg/puff
Study NCT01409928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND (Allergan, Inc.)
Description: Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
Study NCT03115996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3918
Description: Intravenous (IV) or Subcutaneous (SC)
Study NCT03115996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT03358914 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Completion of surveys
Study NCT02649257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Study NCT02649257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraocular lens (MC 6125 AS)
Study NCT02649257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsular tension ring (CTR 13/11)
Study NCT04315467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: A one-time infusion of SGM-101
Study NCT04315467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera imaging system
Description: Near infrared camera imaging system
Study NCT02051907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KAM1403 Gel
Study NCT02051907 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: aloevera gel
Study NCT03562767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Cognitive Behavioral Intervention
Description: This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
Study NCT03562767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Intervention
Description: This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
Study NCT04484350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: 10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)